Simultaneous integrated boost plan comparison of volumetric-modulated arc therapy and sliding window intensity-modulated radiotherapy for whole pelvis irradiation of locally advanced prostate cancer

被引:13
作者
Riou, Olivier [1 ]
de la Mothe, Pauline Regnault [2 ]
Azria, David [1 ]
Ailleres, Norbert [1 ]
Dubois, Jean-Bernard [1 ]
Fenoglietto, Pascal [1 ]
机构
[1] Montpellier Canc Inst, Dept Radiat Oncol, Montpellier, France
[2] Univ Poitiers Hosp, Dept Radiat Oncol, Poitiers, France
关键词
prostate cancer; volumetric-modulated arc therapy; intensity-modulated radiotherapy; whole pelvis irradiation; simultaneous integrated boost plan; organs-at-risk sparing; target volume coverage; RADIATION-THERAPY; ALPHA/BETA RATIO; TUMOR-CONTROL; TRIAL; IMRT;
D O I
10.1120/jacmp.v14i4.4094
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Concurrent radiotherapy to the pelvis plus a prostate boost with long-term androgen deprivation is a standard of care for locally advanced prostate cancer. IMRT has the ability to deliver highly conformal dose to the target while lowering irradiation of critical organs around the prostate. Volumetric-modulated arc therapy is able to reduce treatment time, but its impact on organ sparing is still controversial when compared to static gantry IMRT. We compared the two techniques in simultaneous integrated boost plans. Ten patients with locally advanced prostate cancer were included. The planning target volume (PTV) 1 was defined as the pelvic lymph nodes, the prostate, and the seminal vesicles plus setup margins. The PTV2 consisted of the prostate with setup margins. The prescribed doses to PTV1 and PTV2 were 54 Gy in 37 fractions and 74 Gy in 37 fractions, respectively. We compared simultaneous integrated boost plans by means of either a seven coplanar static split fields IMRT, or a one-arc (RA1) and a two-arc (RA2) RapidArc planning. All three techniques allowed acceptable homogeneity and PTV coverage. Static IMRT enabled a better homogeneity for PTV2 than RapidArc techniques. Sliding window IMRT and VMAT permitted to maintain doses to OAR within acceptable levels with a low risk of side effects for each organ. VMAT plans resulted in a clinically and statistically significant reduction in doses to bladder (mean dose IMRT: 50.1 +/- 4.6Gy vs. mean dose RA2: 47.1 +/- 3.9 Gy, p = 0.037), rectum (mean dose IMRT: 44 +/- 4.5 vs. mean dose RA2: 41.6 +/- 5.5 Gy, p = 0.006), and small bowel (V-30 IMRT: 76.47 +/- 14.91% vs. V-30 RA2: 47.49 +/- 16.91%, p = 0.002). Doses to femoral heads were higher with VMAT but within accepted constraints. Our findings suggest that simultaneous integrated boost plans using VMAT and sliding window IMRT allow good OAR sparing while maintaining PTV coverage within acceptable levels.
引用
收藏
页码:26 / 35
页数:10
相关论文
共 24 条
[1]   Controversies in the Treatment of High-Risk Prostate Cancer-what Is the Optimal Combination of Hormonal Therapy and Radiotherapy: A Review of Literature [J].
Al-Mamgani, Abrahim ;
Lebesque, Joos V. ;
Heemsbergen, Wilma D. ;
Tans, Lisa ;
Kirkels, Wim J. ;
Levendag, Peter C. ;
Incrocci, Luca .
PROSTATE, 2010, 70 (07) :701-709
[2]  
[Anonymous], 2010, Journal of the ICRU, V10
[3]   The α/β ratio for prostate cancer:: What is it, really? [J].
Bentzen, SM ;
Ritter, MA .
RADIOTHERAPY AND ONCOLOGY, 2005, 76 (01) :1-3
[4]   External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study [J].
Bolla, Michel ;
Van Tienhoven, Geertjan ;
Warde, Padraig ;
Dubois, Jean Bernard ;
Mirimanoff, Rene-Olivier ;
Storme, Guy ;
Bernier, Jacques ;
Kuten, Abraham ;
Sternberg, Cora ;
Billiet, Ignace ;
Lopez Torecilla, Jose ;
Pfeffer, Raphael ;
Cutajar, Carmel Lino ;
Van der Kwast, Theodore ;
Collette, Laurence .
LANCET ONCOLOGY, 2010, 11 (11) :1066-1073
[5]   Is the α/β value for prostate tumours low enough to be safely used in clinical trials? [J].
Dasu, A. .
CLINICAL ONCOLOGY, 2007, 19 (05) :289-301
[6]   ASSESSING THE ROLE OF VOLUMETRIC MODULATED ARC THERAPY (VMAT) RELATIVE TO IMRT AND HELICAL TOMOTHERAPY IN THE MANAGEMENT OF LOCALIZED, LOCALLY ADVANCED, AND POST-OPERATIVE PROSTATE CANCER [J].
Davidson, Melanie T. M. ;
Blake, Samuel J. ;
Batchelar, Deidre L. ;
Cheung, Patrick ;
Mah, Katherine .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2011, 80 (05) :1550-1558
[7]   EAU Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Treatment of Clinically Localised Disease [J].
Heidenreich, Axel ;
Bellmunt, Joaquim ;
Bolla, Michel ;
Joniau, Steven ;
Mason, Malcolm ;
Matveev, Vsevolod ;
Mottet, Nicolas ;
Schmid, Hans-Peter ;
van der Kwast, Theo ;
Wiegel, Thomas ;
Zattoni, Filliberto .
EUROPEAN UROLOGY, 2011, 59 (01) :61-71
[8]   Ten-year follow-up of radiation therapy oncology group protocol 92-02: A phase III trial of the duration of elective androgen deprivation in locally advanced prostate cancer [J].
Horwitz, Eric M. ;
Bae, Kyounghwa ;
Hanks, Gerald E. ;
Porter, Arthur ;
Grignon, David J. ;
Brereton, Harmar D. ;
Venkatesan, Varagur ;
Lawton, Colleen A. ;
Rosenthal, Seth A. ;
Sandler, Howard M. ;
Shipley, William U. .
JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15) :2497-2504
[9]   High dose for prostate irradiation with image guided radiotherapy: Contribution of intensity modulation arctherapy [J].
Jouyaux, F. ;
De Crevoisier, R. ;
Manens, J. -P. ;
Bellec, J. ;
Cazoulat, G. ;
Haigron, P. ;
Chira, C. ;
Le Prise, E. ;
Lafond, C. .
CANCER RADIOTHERAPIE, 2010, 14 (08) :679-689
[10]   RapidArc volumetric modulated therapy planning for prostate cancer patients [J].
Kjaer-Kristoffersen, Flemming ;
Ohlhues, Lars ;
Medin, Joakim ;
Korreman, Stine .
ACTA ONCOLOGICA, 2009, 48 (02) :227-232